Anti-CD20 Directed Therapy of B Cell Lymphomas: Are New Agents Really Better? | Current Oncology Reports
CD20 positive CD8 T cells are a unique and transcriptionally-distinct subset of T cells with distinct transmigration properties | Scientific Reports
Frontiers | Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic
CD20 - IHC Primary Antibodies-FR
CD-20 - Micromega
Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia: from uncertainties to promises | Immunotherapy
The regulation and function of CD20: an “enigma” of B-cell biology and targeted therapy | Haematologica
An Overview of CD20 Monoclonal Antibodies Drugs- CUSABIO
Structure of CD20 in complex with the therapeutic monoclonal antibody rituximab | Science
The future of anti-CD 20 monoclonal antibodies : are we making progress ? | Semantic Scholar
CD20 — Wikipédia
Frontiers | Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic
Clinical Perspectives on the Molecular and Pharmacological Attributes of Anti-CD20 Therapies for Multiple Sclerosis | CNS Drugs
Cells | Free Full-Text | Ocrelizumab Depletes CD20+ T Cells in Multiple Sclerosis Patients
Brain Sciences | Free Full-Text | Anti-CD20 Agents for Multiple Sclerosis: Spotlight on Ocrelizumab and Ofatumumab
CD20 — Wikipédia
CD20-based Immunotherapy of B-cell Derived Hematologic Malignancies | Bentham Science
CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure | Haematologica
The future of anti-CD20 monoclonal antibodies: are we making progress? - ScienceDirect
Frontiers | Anti-CD20 B Cell Treatment for Relapsing Multiple Sclerosis
Anti-CD20 Antibody Therapy for B-Cell Lymphomas | NEJM
